CLINUVEL starts SCENESSE supply into China
- CLINUVEL and Winhealth sign Collaboration Agreement to serve Chinese EPP population
- CLINUVEL remains responsible for clinical care and pharmacovigilance, Winhealth in charge of hospital management
- Named Patient Program (NPP) initiated to supply SCENESSE® to 10 Chinese EPP patients
- Local Chinese subsidies in place for EPP patients
- NPP data, FDA and EMA submissioncount towards NMPA (Chinese regulatory authority) submission.
http://www.clinuvel.com/clinuvel-starts-scenesse-supply-into-china-2
http://en.winhealth.hk/
http://www.clinuvel.com/investors-area/news-2/media-release-scenesse-to-be-prescribed-in-china
News: CUV UPDATE 1-U.S. FDA approves Clinuvel Pharma's rare genetic disorder treatment, page-122
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.23 |
Change
-0.130(0.85%) |
Mkt cap ! $769.1M | |||
| Open | High | Low | Value | Volume |
| $15.30 | $15.55 | $15.13 | $145.2K | 9.526K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 52 | $15.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.20 | 63 | 5 |
View Market Depth
| Last trade - 10.38am 18/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |